

412 Rec'd PCT/PTO 13 JUL 1999

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

045636-5027

U.S. Application No.
Unassigned

09/341539

International Application. No.

International Filing Date

Priority Date Claimed

PCT/FR98/00063

14 January 1998

14 January 1997

Title of Invention

**METHOD FOR SCREENING SUBSTANCES WITH THERAPEUTIC ACTION IN THE
TREATMENT OF TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES**

Applicants For DO/EO/US

Jean-Philippe DESLYS, Vincent BERINGUE and Corinne LASMEZAS

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventors (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 14. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☒ Other items or information:
 - a. ☒ WIPO Publication WO98/00063
 - b. ☒ International Search Report
 - c. ☒ PCT/RO/101
 - d. ☒ PCT/RO/105
 - e. ☒ PCT/IB/301
 - f. ☒ PCT/IB/304
 - g. ☒ PCT/IB/308

U.S. APPLICATION NO.

INTERNATIONAL APPLICATION NO.

ATTORNEY DOCKET NUMBER

Unassigned

09/341539

PCT/FR98/00063

045636-5027

15. [X] The following fees are submitted:
- Basic National Fee (37 CFR 1.492(a)(1)-(5)):**
- Search Report has been prepared by the EPO or JPO.....\$840.00
- International preliminary examination fee paid to
USPTO (37 CFR 1.482).....\$670.00
- No international preliminary examination fee paid to
USPTO (37 CFR 1.482) but international search fee
paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00
- Neither international preliminary examination fee
(37 CFR 1.482) nor international search fee
(37 CFR 1.445(a)(2)) paid to USPTO.....\$970.00
- International preliminary examination fee paid to USPTO
(37 CFR 1.482) and all claims satisfied provisions
of PCT Article 33(2)-(4).....\$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 840.00

Surcharge of \$130.00 for furnishing the oath or declaration later than
[] 20 [] 30 months from the earliest claimed priority date
(37 CFR 1.492(e)).

Claims	Number Filed	Number Extra	Rate	
Total Claims	14 - 20 =	0	X \$18.00	\$
Independent Claims	1 - 3 =	0	X \$78.00	\$
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$

TOTAL OF ABOVE CALCULATIONS = \$840.00

Reduction by 1/2 for filing by small entity, if applicable. Verified
Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)

SUBTOTAL = \$840.00

Processing fee of \$130.00 for furnishing the English translation later
than [] 20 [] 30 months from the earliest claimed priority date
(37 CFR 1.492(f)).

TOTAL NATIONAL FEE = \$840.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The
assignment must be accompanied by an appropriate cover sheet
(37 CFR 3.28, 3.31). \$40.00 per property

TOTAL FEES ENCLOSED = \$840.00

Amount to be	
refunded	\$
charged	\$

- a. [X] A check in the amount of **\$840.00** to cover the above fees is enclosed.
- b. [] Please charge my Deposit Account No. 50-0310 in the amount of \$-0-
to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. [X] **Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to
charge any additional fees during the entire pendency of this application including fees due under 37 CFR §1.16
and §1.17 which may be required, or credit any overpayment to Deposit Account No. 50-0310.

Customer No. 009629

SEND ALL CORRESPONDENCE TO:

Morgan, Lewis & Bockius LLP

1800 M Street, N.W.

Washington, D.C. 20036

(202) 467-7000

Reid G. Adler
Reid G. Adler
Reg. No. 30,988

Submitted: July 13, 1999

09/341539
80 Rec'd PCT/PTO 13 JUL 1999

PATENT
ATTORNEY DOCKET NO.: 045636-5027

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Jean-Philippe DESLYS et al.)
)
Application No.: Unassigned) Group Art Unit: Unassigned
(National Stage Application of)
PCT/FR98/00063 filed January 14, 1998))
)
Filed: July 13, 1999) Examiner: Unassigned
)
For: **METHOD FOR SCREENING SUBSTANCES WITH**)
THERAPEUTIC ACTION IN THE TREATMENT OF)
TRANSMISSIBLE SUBACUTE SPONGIFORM)
ENCEPHALOPATHIES)

ATTN: BOX PCT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Prior to the examination of the above-identified application on the merits, please amend
the application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

Claim 1, line 1, delete "Method" and substitute --A method--.

Claim 2, line 1, delete "Method" and substitute --A method--.

3. (Amended) A [Method] method of screening according to Claim 1 [or Claim 2], characterized in that in step a) the said NCTA is administered by the intraperitoneal route, at a dose corresponding to an inoculum of NCTA, between 0.001% and 10% (weight/volume) (LD_{50} between 10^3 and 10^7).

4. (Amended) A [Method] method of screening according to [any one of Claims 1 to 3,] Claim 1, characterized in that in step d) the said method of isolation is selected such that the ratio: maximum level detectable in the spleen/cut off is greater than 2 or such that a $\frac{1}{2}$ dilution of the final sample obtained still provides a detection signal.

5. (Amended) A [Method] method of screening according to [any one of Claims 1 to 4,] Claim 1, characterized in that in step d) the said method of isolation of PrPres comprises a separation in a single step.

6. (Amended) A [Method] method of screening according to [any one of Claims 1 to 4,] Claim 1, characterized in that in step e) the PrPres is detected by immunoassay.

7. (Amended) A [Method] method of isolating PrPres, from an organ or a tissue, in particular the spleen or the brain, which is capable of being used in a method according to [any one of Claims 1 to 6,] Claim 1, characterized in that it comprises essentially the following steps:

(i) homogenization of organ or tissue, collected after sacrificing the animal, by mechanical grinding in a homogenization buffer, followed by calibration of the homogenate, for the production of a homogenate comprising, in weight/volume, from 5 to 50% of the said organ or tissue;

(ii) specific extraction of PrPres comprising a single separation step, by treating the homogenate obtained in step (i) by incubating the suspension obtained with a protease and an anionic detergent capable of promoting the aggregation of the PrPres in a suitable buffer and separation of the PrPres, by a single ultracentrifugation at 480,000-1,200,000 g.h, preferably for 2-4 hours, for example at 240,000- 300,000g for 2 to 4h, preferably at 20-22°C, of the said suspension, deposited on a buffer cushion having a density of between 1.02 and 1.08, at 20°C and recovering the centrifugation pellet comprising the said PrPres; and, if necessary,

(iii) purification of the PrPres by suspending the centrifugation pellet obtained in (ii) in a Laemmli buffer comprising 1-5% SDS, incubating in this buffer at 100°C for 2-10 minutes and centrifuging at 12,000-15,000 g for 10-15 minutes at 16-22°C.

8. (Amended) A [Method] method of isolating PrPres, from an organ or a tissue, in particular the spleen or the brain, which is capable of being used in a method according to [any one of Claims 1 to 6,] Claim 1, characterized in that it comprises essentially the following steps:

(i) homogenization of organ or tissue, collected after sacrificing the animal, by mechanical grinding in a homogenization buffer, followed by the addition, to the homogenate obtained, of a salt having a high ionic strength and capable of promoting the aggregation of the PrPres in a 1:1 (v/v) ratio, followed by calibration of the homogenate, for the production of a homogenate comprising, in weight/volume, from 5 to 50% of the said organ or tissue;

(ii) specific extraction of PrPres by treating the homogenate obtained in step (i) by incubating the suspension obtained with solution comprising a protease and an anionic detergent capable of promoting the aggregation of the PrPres, and a single separation of the PrPres, by centrifugation at 25,000-60,000 g.h, for example at 25,000-30,000 g for 1 to 2 h, preferably at 16-22°C, of the suspension obtained, deposited on a buffer cushion having a density of between 1.02 and 1.08, at 20°C, and recovering the centrifugation pellet comprising the said PrPres; and, if necessary,

(iii) purification of the PrPres by suspending the centrifugation pellet obtained in (ii) in a Laemmli buffer comprising 1-5% SDS, incubating in this buffer at 100°C for 2-10 minutes and centrifuging at 12,000-15,000 g for 10-15 minutes at 16-22°C.

9. (Amended) A [Method] method according to Claim 7 [or 8], characterized in that the homogenization buffer in step (i) is in particular a neutral buffer such as water or an isotonic buffer such as 5% glucose.

10. (Amended) A [Method] method according to Claim 7 [or Claim 8], characterized in that in step (ii), prior to the centrifugation, at least one protease inhibitor is added.

11. (Amended) A [Method] method according to Claim 7 [or Claim 8], characterized in that in step (ii) the centrifugation is preferably carried out after depositing the suspension containing the PrPres on a 6-20% sucrose cushion.

12. (Amended) A [Method] method according to Claim 8, characterized in that during the extraction step (ii) the solution used for the extraction comprises an anionic detergent capable of promoting the aggregation of the PrPres and a zwitterionic detergent, such as a sulphobetaine, preferably the sulphobetaine SB 3-14 at 1-2%, in a 1:1 (v/v) ratio.

13. (Amended) A [Method] method according to Claim 8, characterized in that in the extraction step (ii) the centrifugation is preferably carried out after depositing the suspension containing the PrPres on a cushion comprising, in a mixture, 6-20% sucrose and a sulphobetaine.

Cancel claim 14.

Please add new claim 15.

--15. A method of detecting the presence of PrPres in an organ or a tissue, comprising isolating PrPres from the organ or tissue in accordance with the method of claim 7, and contacting the isolated PrPres with an antibody capable of specific binding to the PrPres.--

REMARKS


No new matter has been introduced by this Preliminary Amendment, and the changes involved are necessary to present proper U.S. English spellings and usage for the intended claims, as well as to eliminate improper multiple dependencies and to provide proper claim format for prosecution in the United States Patent & Trademark Office.

If there are any additional fees due in connection with the filing of this Preliminary Amendment, please charge the fees to our Deposit Account No. 50-0310.

Respectfully submitted

MORGAN, LEWIS & BOCKIUS LLP

By: _____



Reid G. Adler
Reg. No. 30,988

Dated: July 13, 1999

Customer No. 009629

MORGAN, LEWIS & BOCKIUS LLP

1800 M Street, N.W.

Washington, DC 20036

202-467-7000

METHOD FOR SCREENING SUBSTANCES WITH THERAPEUTIC ACTION
IN THE TREATMENT OF TRANSMISSIBLE SUBACUTE SPONGIFORM
ENCEPHALOPATHIES

5 The present invention relates to a method for
screening substances capable of having a therapeutic
action in the treatment of transmissible subacute
spongiform encephalopathies (TSSEs) or so-called prion
diseases, which comprises a step of isolating the
10 PrPres from the spleen; the present invention also
relates to methods for isolating the PrPres, which are
particularly suited to the said screening method, and
their applications in particular in the detection of
PrPres.

15 Transmissible subacute spongiform
encephalopathies are caused by nonconventional
transmissible agents (NCTAs), also called prions, whose
precise nature remains unknown to date. TSSEs comprise
essentially Creutzfeldt-Jakob disease, in humans (CJD),
20 scrapie, in sheep and goats, and bovine spongiform
encephalopathy (BSE), in bovines; other
encephalopathies have been demonstrated in mink or some
wild animals such as red deer and elk.

 The progression of these diseases is always
25 fatal and there is currently no effective treatment.

 In transmissible subacute spongiform
encephalopathies, there is an accumulation of a host
protein, PrP (or prion protein), in an abnormal form
(PrPres), mainly in the central nervous system; PrPres
30 copurifies with the infectivity and its accumulation
precedes the appearance of histological lesions.
In vitro, it is toxic for neuron cultures.

 Two biochemical properties make it possible to
distinguish PrPres from the normal PrP: PrPres is
35 partially resistant to proteases and is insoluble in
nonionic detergents such as Triton-X100.

 The search for new molecules which may be
effective in the treatment of these encephalopathies is
hindered both by the absence of efficient in vitro

09341539-101299

models and the length of time for setting up *in vivo* experimental models, such as experimental scrapie in hamsters (80 to 365 days), or experimental scrapie in mice (180 to 550 days).

5 Consequently, the inventors set themselves the objective of providing an effective and reliable method of screening which does not exhibit the disadvantages of the experimental models currently used and which is more suitable for the requirements of practical use, in
10 particular in that the evaluation of the action of the substances to be tested can be carried out in less than two months.

To do this, the inventors have found a reliable marker and have developed a reproducible protocol.

15 The subject of the present invention is a method for screening substances capable of having therapeutic action in the treatment of transmissible subacute spongiform encephalopathies (TSSEs or so-called prion diseases), characterized in that it
20 comprises the following steps:

a) inoculation at time t_A , into at least one laboratory animal such as a rodent, mouse or hamster (preferably several, divided into batches), by any appropriate route, of a nonconventional transmissible
25 agent (NCTA) or prion;

b) administration to the said laboratory animal, by any appropriate route, of either a substance to be screened (test animal), or of a placebo (negative control animal), within a period between $t_A - 15$ days
30 and t_C , corresponding to the time when the PrPres level in the spleen of the said laboratory animal is at maximum or within a period between t_B , corresponding to the time of the first detection of PrPres in the spleen of the said laboratory animal and t_C ; t_B being between
35 t_A and $t_A + 15$ and t_C being between $t_A + 20$ and $t_A + 30$, preferably between $t_A + 25$ and $t_A + 30$;

c) sacrificing of the animals within a time interval between t_B and t_C , preferably at t_C , and collecting of the spleen;

09341539-101299

d) isolation of the PrPres from the spleens collected, according to a suitable method of isolation comprising the homogenization of the spleen, followed by a specific extraction of the PrPres comprising a
5 single separation step, from the homogenate obtained, and optionally the purification of the PrPres;

e) semiquantification of the PrPres obtained in step (d) by detection of the said PrPres by any appropriate method, producing a specific signal,
10 followed by a comparison of the signal obtained with a calibration series of dilutions of a positive control consisting of a brain homogenate from an animal at the terminal stage of the disease; and

f) selection of the screened substances as a
15 candidate for the treatment of transmissible subacute spongiform encephalopathies, if the PrPres level obtained in the spleen of the test animal, in step e), is reduced by at least a factor of 2 compared with the level obtained under the same conditions with the
20 negative control animal.

The times t_A , t_B and t_C are expressed in days;
 $t_A = D0$.

Indeed, the inventors have found, unexpectedly, that substances which increase the survival of infected
25 animals, regardless of the mode of inoculation (peripheral or intracerebral), also result in a delay in the accumulation of PrPres in the spleen, detected under standardized conditions.

Standardized conditions are understood to mean,
30 for the purposes of the present invention, conditions in which the following parameters are selected:

- NCTA selected,
- route of administration of NCTA,
- method of isolation of the PrPres from the
35 spleen.

For a strain selected from a given animal, at the terminal stage of the disease, the infectious titer is constant.

09341539-101299

00341539 101299

The detection of PrPres in the spleen makes it possible to observe much more rapidly the effects of the molecules to be tested, in particular the inhibition of the accumulation of PrPres, either within
5 the hours following the inoculation (capture of the inoculum by the spleen and detection of a PrPres peak between t_A and $t_A + 1-2$ days), or between 5 and 15 days after the infection; t_B corresponds both to the detection of the peak at the time of capture of the
10 inoculum and to the detection of the neosynthesized PrPres; this is the reason why t_B is between t_A and $t_A + 15$; these t_B and t_C values may vary within the ranges defined above, depending on the NCTA and the laboratory animal (mouse) selected; for example, when
15 the NCTA corresponds to the murine strain C506M3 inoculated by the intraperitoneal route, in the C57BL/6 mouse, the neosynthesized PrPres may be detected in 100% of cases, from the 5th day post-infection (p.i.) (t_B) and a plateau is observed from the 30th day p.i.
20 (t_C).

Such a method therefore makes it possible to select molecules capable of preventing the accumulation of PrPres; such molecules are considered to be capable of exhibiting therapeutic action in the treatment of
25 TSSEs.

In accordance with the invention:

*** in step a):**

- the NCTA corresponds to a strain stabilized in the host animal, that is to say which exhibits
30 stable characteristics in this host animal after several passages and in particular the following characteristics: identical period before the appearance of the disease and identical lesional profile during passages in all animals (degree of vacuolation of
35 various parts of the brain); it corresponds to any strain stabilized under the abovementioned conditions, inducing a premature accumulation of PrPres in the spleen of the host animal, such as scrapie strains or bovine encephalopathy strains, in particular the

scrapie strains called Chandler, ME7, 139A (M.E. Bruce et al., *Scrapie strain variation and its implication in Current topics in Microbiology and Immunology: Transmissible Spongiform Encephalopathies, Scrapie, BSE and related disorders*, 1991, 172, 125-138), C506M3 (C.I. Lasmézas et al., *J. Gen. Virol.*, 1996, 77, 1601-1609) or 263K (R.H. Kimberlin et al., *J. Gen. Virol.*, 1977, 34, 295-304 and 1978, 39, 487-496) or the BSE strains called 4PB1 (C.I. Lasmézas et al., 1996, cited above) and 301V (C.F. Farquhar et al., *J. Gen. Virol.*, 1996, 77, 1941-1946);

- the said NCTA is preferably administered in a buffer suited to the route of administration selected in the form either of a crude tissue, preferably brain, homogenate, or of a PrPres pellet, obtained by appropriate centrifugation, from a crude tissue, preferably brain, homogenate;

- the said NCTA may be administered by any route (oral route, parenteral route), preferably by the intraperitoneal route, at a dose corresponding to an inoculum of NCTA, between 0.001% and 10% (weight/volume) (LD_{50} between 10^3 and 10^7);

- the said laboratory animal is preferably a rodent (mouse or hamster, for example).

*** In step b):**

- the substance to be screened is administered by the oral or parenteral route;

- if the treatment is started between t_B and t_C , (that is to say when the PrPres in the spleen is constantly detectable), the model according to the invention makes it possible to study only the action of the substance to be screened on the NCTA inoculated during replication at the sites of replication (target cells), whereas if it is administered before t_B , for example at t_A , the model according to the invention makes it possible to study, in addition, the action of the substance to be screened before the NCTA has reached its target cells in the spleen.

*** In step d):**

09341539.101299

09341539 "101299

- depending on the sequence of steps selected among the known protein isolation techniques, namely the methods based on molecular size, such as centrifugation, the methods based on differences in solubility such as *salting in* and *salting out* or fractionation by solvents or the methods based on electrical charge, the degree of purification and the yield will be different. Within the framework of the present invention, it is necessary to select a reliable and sensitive method which makes it possible to obtain a detection threshold such that the ratio: maximum level detectable in the spleen/cut off is as high as possible, preferably greater than 2 or such that when a 1/2 dilution of the final sample obtained is carried out, a detection signal is still obtained;

- sequences of steps preferred are described hereinafter: they have the advantage, over the methods of isolation previously described, of having high reliability and high sensitivity, because the actual extraction comprises only a single separation step and because of the particular selection of the sequence of steps, whereas in the methods previously described (R.E. Race et al., J. Gen. Virol., 1992, 73, 3319-3323; Doi et al., J. Gen. Virol., 1988, 69, 955-960; T. Muramoto et al., Am. J. Pathol., 1993, 143, 5 1470-1479; Farquhar C.F. et al., Gen. Virol., 1994, 75, 495-504 and J. Gen. Virol., 1996, 77, 1941-1946), the extraction comprises several separation steps and leads to an imprecision as regards the quantification, and/or the sensitivity of these methods is insufficient to obtain a fine detection threshold and a fine quantification and in particular to effectively detect a large variation in the PrPres level.

*** In step e):**

- the PrPres is in particular detected by immunoassay (Western blot for example).

The subject of the present invention is also a method for isolating PrPres, from an organ or a tissue,

in particular the spleen or the brain, characterized in that it comprises essentially the following steps:

(i) homogenization of organ or tissue, collected after sacrificing the animal, by mechanical grinding in a homogenization buffer, followed by calibration of the homogenate, for the production of a homogenate comprising, in weight/volume, from 5 to 50% of the said organ or tissue;

(ii) specific extraction of PrPres comprising a single separation step, by treating the homogenate obtained in step (i) by incubating the suspension obtained with a protease and an anionic detergent (surfactant), capable of promoting the aggregation of the PrPres, such as 10-30% sarkosyl (lauroyl sarcosine) in a suitable buffer and separation of the PrPres, by a single ultracentrifugation at 480,000-1,200,000 g.h, preferably for 2-4 hours, for example at 240,000-300,000 g for 2 to 4 h, preferably at 20-22°C, of the suspension obtained, deposited on a buffer cushion having a density of between 1.02 and 1.08, at 20°C and recovering the centrifugation pellet comprising the said PrPres; and, if necessary,

(iii) purification of the PrPres by suspending the centrifugation pellet obtained in (ii) in a Laemmli buffer comprising 1-5% SDS, incubating in this buffer at 100°C for 2-10 minutes and centrifuging at 12,000-15,000 g for 10-15 minutes at 16-22°C.

The said PrPres thus purified may then be separated by any appropriate technique such as electrophoresis (polyacrylamide gel electrophoresis, for example) or immunocapture, from the centrifugation supernatant.

In accordance with this method, the homogenization buffer in step (i) is in particular a neutral buffer such as water or an isotonic buffer such as 5% glucose.

Also in accordance with the invention, during the extraction step (ii), the ultracentrifugation is

carried out after depositing the suspension containing the PrPres on a 6-20% sucrose cushion.

As a variant, the subject of the present invention is also a method in which the extraction comprises a single step for the preparation of the PrPres, and does not require ultracentrifugation; such a method for isolating PrPres, from an organ or tissue, in particular the spleen or the brain, is characterized in that it comprises essentially the following steps:

10 (i) homogenization of organ or tissue, collected after sacrificing the animal, by mechanical grinding in a homogenization buffer, followed by the addition, to the homogenate obtained, of a salt having a high ionic strength and capable of promoting the aggregation of the PrPres, such as 10-30% NaCl, in a 1:1 (v/v) ratio, followed by calibration of the homogenate, for the production of a homogenate comprising, in weight/volume, from 5 to 50% of the said organ or tissue;

20 (ii) specific extraction of PrPres by treating the homogenate obtained in step (i) by incubating the suspension obtained with a protease and an anionic detergent capable of promoting the aggregation of the PrPres, such as 10-30% sarkosyl and a single separation of the PrPres, by centrifugation at 25,000-60,000 g.h, for example at 25,000-30,000 g for 1 to 2 h, preferably at 16-22°C, of the suspension obtained, deposited on a buffer cushion having a density of between 1.02 and 1.08, at 20°C, and recovering the centrifugation pellet comprising the said PrPres; and, if necessary,

30 (iii) purification of the PrPres by suspending the centrifugation pellet obtained in (ii) in a Laemmli buffer comprising 1-5% SDS, incubating in this buffer at 100°C for 2-10 minutes and centrifuging at 12,000-15,000 g for 10-15 minutes at 16-22°C.

The said PrPres thus purified may then be separated by any appropriate technique such as electrophoresis (polyacrylamide gel electrophoresis,

09341539.101299

for example) or immunocapture, from the centrifugation supernatant.

In accordance with this method, the homogenization buffer in step (i) is in particular a neutral buffer such as water or an isotonic buffer such as 5% glucose.

Also in accordance with the invention:

. during the extraction step (ii), the solution used for the extraction comprises an anionic detergent capable of promoting the aggregation of the PrPres and a detergent having protein-renaturing properties, such as a zwitterionic detergent, such as a sulphobetaine, preferably the sulphobetaine SB 3-14 at 1-2%, in a 1:1 (v/v) ratio;

. during the extraction step (ii), but prior to the centrifugation, at least one protease inhibitor is added;

. the centrifugation depending on the extraction step (ii) is preferably carried out after depositing the suspension containing the PrPres on a 6-20% sucrose cushion or a 6-20% sucrose cushion and a sulphobetaine.

The PrPres can then be detected by any appropriate specific method.

Surprisingly, these methods for isolating PrPres, from the spleen, comprising an extraction in a single step, do not bring about a cumulative loss of PrPres and can be directly used without modification, to extract the PrPres from any other tissue.

In addition to the preceding features, the invention also comprises other features, which will emerge from the description which follows, which refers to exemplary embodiments of the method which is the subject of the present invention and to the accompanying drawings in which:

- Figure 1 illustrates the protocol used in a method of screening according to the invention;

- Figure 2 represents a polyacrylamide gel showing the inhibition of the accumulation of PrPres in

09341539-101299

the spleens of mice infected with the strain C506M3 and treated with amphotericin B (AmB) (the molecular weight ladder was established with Amersham prestained markers);

5 - Figure 3, in the form of a histogram, illustrates the inhibition of the accumulation of PrPres in the same mouse, after treatment with amphotericin B or ABLC® (AmB Lipid Complex), compared with a negative control animal, treated with a placebo
10 and in which there is no inhibition of the said accumulation;

 - Figure 4 and 5 illustrate the kinetics of accumulation of PrPres in the spleen of C57BL/6 mice inoculated i.p. with the strain C506M3 (0-28 days post-
15 inoculation);

 - Figure 6 illustrates the role of the composition of the extraction buffer in the purification yield of PrPres;

 - Figure 7 illustrates the treatment protocol
20 carried out to test dextran sulphate (DS500);

 - Figure 8 illustrates the accumulation of PrPres in spleens of C57BL/6 mice infected by the intraperitoneal route with the C506M3 strain and treated 2 h before inoculation with dextran sulphate
25 DS500.

It should be understood, however, that these examples are given solely by way of illustration of the subject of the invention and do not constitute in any manner a limitation thereto.

30 **EXAMPLE 1** : Study of the accumulation of PrPres in spleens of C57BL/6 mice infected by the intraperitoneal (ip) route with the C506M3 strain and treated for 1 or 2 weeks (6 days/week), from t_A+15 after inoculation, with amphotericin B (AmB) and its derivatives;
35 isolation of the PrPres present in the spleen by the method of isolation comprising an ultracentrifugation, as described above.

. Step a) of the method of screening :
inoculation

at t_A , C57BL/6 mice are inoculated by the intraperitoneal route with 100 μ l of 2% brain homogenate in 5% glucose, from an infected mouse at the terminal stage of experimental scrapie (strain C506M3).

5 . Step b) of the method of screening : administration of a substance capable of having a therapeutic action or administration of a placebo

at t_A+15 days (\rightarrow period between t_B and t_C), the C57BL/6 mice are divided into various batches and are
10 treated:

- either with amphotericin B, at the rate of 1 mg/kg (AmB),

- or with ABLC[®], at the rate of 10 mg/kg, for 6 days (1) or 12 days (2), in accordance with Figure 1,

15 - or with a placebo.

. Step c) of the method of screening : sacrificing the animals.

At t_A+21 days (\rightarrow period between t_B and t_C) or at t_A+28 days (\rightarrow at t_C) the mice are sacrificed by
20 breaking the cervical vertebrae; the spleens are immediately collected, in accordance with Figure 1, and either stored at -80°C , or used while fresh.

. Step d) of the method of screening : isolation of the PrPres

25 The spleens collected are ground and homogenized at 10% (weight/volume) in a 5% glucose solution. The homogenate obtained is calibrated by passing through a suitable syringe.

The 10% homogenate (200 μ l) is then treated
30 with proteinase K (10 μ g/ml), at 37°C , for one hour; the digestion is blocked with the aid of 5 mM phenylmethylsulphonyl fluoride (PMSF). After addition of 20% sarkosyl in 10 mM Tris, pH 7.4, the samples are incubated for 15 minutes at room temperature. They are
35 then centrifuged at 245,000 g for 4 hours at 20°C , on a 10% sucrose cushion (100-300 μ l) (Beckman TL100 ultracentrifuge).

The pellets are resuspended in a Laemmli buffer, incubated for 5 minutes at 100°C , and then the

00344539-101299

samples obtained are subjected to centrifugation at 15,000 g, for 15 minutes at 16°C.

. Step e) of the method of screening according to the invention : detection of the PrPres in the samples

The samples obtained are used to carry out an SDS-PAGE electrophoresis (12% polyacrylamide gel loaded with the equivalent of 10 mg of spleen) and transferred to a nitrocellulose membrane, under the conditions described by Towbin et al. (Proc. Natl. Acad. Sci. USA, 1979, 76, 4350-4354) or by C.I. Lasmézas et al. (J. Gen. Virol., 1996, cited above). The immunodetection of the PrPres was carried out with the antiserum 007 JB (R. Demaimay et al., Journal of Virology, 1997, 71, 12, 9685-9689), directed against the peptide 90-108 of the murine PrP at 1/2500) and peroxidase-conjugated anti-rabbit goat Ig's (1/2500). The immunoreactivity is revealed by chemiluminescence (ECL, Amersham), quantified and visualized on autoradiography films, as illustrated in Figure 2, for the untreated animals and the animals treated for 6 days with AmB at 1 mg/kg and sacrificed at t_A+28 days, that is to say one week after the end of the treatment.

The antibodies are obtained by coupling the said peptide (Néosystem, Strasbourg) to KLH, followed by subcutaneous injection into the dorsal region of "New Zealand" rabbits of an emulsion comprising the said coupled peptide and of complete Freund's adjuvant (R. Demaimay et al., Journal of Virology, 1997, 71, 12, 9685-9689).

* Step f) of the method of screening according to the invention : selection of the screened substance

Figure 3 illustrates the results obtained for the untreated animals, the animals treated with AmB, 1 mg/kg sacrificed at t_A+21 or at t_A+28 and the animals treated with ABLC® 6 days (1) or 12 days (2) and sacrificed at t_A+21 or at t_A+28 : both for the animals treated with AmB and with ABLC®, a significant inhibition of the accumulation of PrPres is observed;

09341539 101299

to construct the histogram, the quantities of PrPres detected in the spleen are compared with a linear series of dilutions of purified PrPres according to the same method as that described above, from a brain
5 homogenate of animals at the terminal stage of the disease (positive control).

Figures 4 and 5 illustrate the kinetics of accumulation of PrPres in the spleen of C57BL/6 mice, inoculated with the C506M3 strain at t_A , under the same
10 conditions as above, for 28 days and untreated: a gradual increase is observed up to t_A+30 (\rightarrow at t_C); a plateau is observed from t_A+30 .

EXAMPLE 2 : Study of the accumulation of PrPres in spleens of C57BL/6 mice infected by the intraperitoneal
15 (ip) route with the C506M3 strain and treated for 1 or 2 weeks (6 days/week), from t_A+15 after inoculation, with amphotericin B (AmB) and its derivatives; isolation of the PrPres by the method including no ultracentrifugation.

20 Steps a), b), c), e) and f) are identical to those of Example 1.

Step d) of isolation of the PrPres from the spleens of mice is carried out as follows:

The spleens collected are ground and
25 homogenized at 20% (weight/volume) in a solution containing 5% glucose; 200 μ l of 20% NaCl are added to 200 μ l of homogenate (1:1, v/v). The homogenate obtained is calibrated by passing through a suitable syringe.

30 200 μ l of detergent (20% sarkosyl and 2% sulphobetaine (SB3.14 Calbiochem)) and proteinase K at 10 μ g/ml are added to 200 μ l of 20% homogenate, and then the mixture is incubated at 37°C, for one hour.

The samples are then centrifuged at 30,000 g
35 for 2 hours at 22°C, on 200 μ l of a cushion comprising 10% sucrose and 0.1% sulphobetaine, as final concentrations (Eppendorf rotor; ALC 4239R centrifuge).

Figure 6 illustrates the purification yields obtained with various extraction buffer compositions

09341539-10390

(representation in the form of a histogram and of a Western blot): 1: yield control (total homogenate); 2: 10% sarkosyl/10% NaCl/10 mM Tris/1% SB3-14; 3: 10% sarkosyl/10% NaCl/10 mM Tris; 4: 10% sarkosyl/10% NaCl; 5: 10% sarkosyl.

The pellets are resuspended in a Laemmli buffer, incubated for 5 minutes at 100°C, and then the samples obtained are subjected to a second centrifugation at 15,000 g, for 15 minutes at 16°C.

10 **EXAMPLE 3** : Study of the accumulation of the PrPres in spleens of C57BL/6 mice infected by the intraperitoneal route with the C506M3 strain and treated at t_A -2 hours with dextran sulphate (DS500).

15 The treatment protocol is summarized in Figure 7.

. Step b) of the method of screening : administration of a substance capable of having a therapeutic action.

20 At t_A -2 hours (that is to say 2 hours before the inoculation of the infectious strain), C57BL/6 mice are divided into various batches:

- untreated mice
 - and mice treated with dextran sulphate (DS500) at 25 mg/kg (single injection at t_A -2 hours).
- 25 - Step a) of the method of screening : inoculation

At t_A , the C57BL/6 mice are inoculated by the intraperitoneal route with 100 μ l of 2% brain homogenate in 5% glucose, from an infected mouse at the 30 terminal stage of experimental scrapie [strain C506M3].

. Step c) of the method of screening : sacrificing the animals

At t_A +2 hours, t_A +7 days and t_A +22 days, the mice are sacrificed by breaking the cervical vertebrae; 35 the spleens are immediately collected.

. Step d) of the method of screening : isolation of the PrPres

identical to step d) of Example 2.

09341539.101299

. Step e) of the method of screening according to the invention : detection of the PrPres in the samples.

The samples obtained are used to carry out an SDS-PAGE electrophoresis (12% polyacrylamide gel loaded with the equivalent of 40 mg of spleen for 2 h and 7 days and 10 mg of spleen for 22 days) and transferred to nitrocellulose membrane, under the conditions described by Towbin et al. (Proc. Natl. Acad. Sci. USA, 1979, 76, 4350-4354) or by C.I. Lasmézas et al. (J. Gen. Virol., 1996, cited above). The immunodetection of the PrPres was carried out with the antiserum 007JB (R. Demaimay et al., J. Virol. 1997, 71, 12, 9685-9689) at 1/5000th, and peroxidase-conjugated anti-rabbit goat Ig's (1/2500). The immunoreactivity is revealed by chemiluminescence (ECL, Amersham), quantified and visualized on autoradiography films, as illustrated in Figure 8, for the untreated animals and the animals treated 2 h before the inoculation with DS500 and sacrificed at $t_A + 2$ h, $t_A + 7$ days and $t_A + 22$ days.

* Step f) of the method of screening according to the invention : selection of the screened substance

Figure 8 illustrates the results obtained; a significant inhibition of the accumulation of PrPres is observed in the treated animals.

As is evident from the above, the invention is not at all limited to those of its embodiments, implementations and applications which have just been described more explicitly; it embraces on the contrary all the variants thereof which may occur to the specialist in this field, without departing from the framework or the scope of the present invention.

CLAIMS

1. Method for screening substances capable of having therapeutic action in the treatment of transmissible subacute spongiform encephalopathies (TSSEs), characterized in that it comprises the following steps:

a) inoculation at time t_A , into at least one laboratory animal selected from the group consisting of rodents, by any appropriate route, of a nonconventional transmissible agent (NCTA);

b) administration to the said laboratory animal, by any appropriate route, of either a substance to be screened (test animal), or of a placebo (negative control animal), within a period between $t_A - 15$ days and t_C , corresponding to the time when the PrPres level in the spleen of the said laboratory animal is at maximum or within a period between t_B , corresponding to the time of the first detection of PrPres in the spleen of the said laboratory animal and t_C ; t_B being between t_A and $t_A + 15$ and t_C being between $t_A + 25$ and $t_A + 30$;

c) sacrificing of the animals within a time interval between t_B and t_C , preferably at t_C , and collecting of the spleen, t_A , t_B and t_C being expressed in days;

d) isolation of the PrPres from each spleen collected, according to a suitable method of isolation comprising the homogenization of the spleen, followed by a specific extraction of the PrPres comprising a single separation step, from the homogenate obtained, and optionally the purification of the PrPres;

e) semiquantification of the PrPres obtained in step (d) by detection of the said PrPres by any appropriate method, producing a specific signal, followed by a comparison of the signal obtained with a calibration series of dilutions of a positive control consisting of a brain homogenate from an animal at the terminal stage of the disease; and

f) selection of the screened substances as a candidate for the treatment of transmissible subacute

09341539.101299

spongiform encephalopathies, if the PrPres level obtained in the spleen of the test animal, in step e), is reduced by at least a factor of 2 compared with the level obtained under the same conditions with the negative control animal.

2. Method of screening according to Claim 1, characterized in that in step a) the said NCTA is preferably administered in a buffer suited to the route of administration selected in the form either of a crude tissue, preferably brain, homogenate, or of a PrPres pellet, obtained by appropriate centrifugation, from a crude tissue, preferably brain, homogenate.

3. Method of screening according to Claim 1 or Claim 2, characterized in that in step a) the said NCTA is administered by the intraperitoneal route, at a dose corresponding to an inoculum of NCTA, between 0.001% and 10% (weight/volume) (LD_{50} between 10^3 and 10^7).

4. Method of screening according to any one of Claims 1 to 3, characterized in that in step d) the said method of isolation is selected such that the ratio: maximum level detectable in the spleen/cut off is greater than 2 or such that a 1/2 dilution of the final sample obtained still provides a detection signal.

5. Method of screening according to any one of Claims 1 to 4, characterized in that in step d) the said method of isolation of the PrPres comprises a separation in a single step.

6. Method of screening according to any one of Claims 1 to 4, characterized in that in step e) the PrPres is detected by immunoassay.

7. Method of isolating PrPres, from an organ or a tissue, in particular the spleen or the brain, which is capable of being used in a method according to any one of Claims 1 to 6, characterized in that it comprises essentially the following steps:

(i) homogenization of organ or tissue, collected after sacrificing the animal, by mechanical grinding in a homogenization buffer, followed by

calibration of the homogenate, for the production of a homogenate comprising, in weight/volume, from 5 to 50% of the said organ or tissue;

(ii) specific extraction of PrPres comprising a single separation step, by treating the homogenate obtained in step (i) by incubating the suspension obtained with a protease and an anionic detergent capable of promoting the aggregation of the PrPres in a suitable buffer and separation of the PrPres, by a single ultracentrifugation at 480,000-1,200,000 g.h, preferably for 2-4 hours, for example at 240,000-300,000 g for 2 to 4 h, preferably at 20-22°C, of the said suspension, deposited on a buffer cushion having a density of between 1.02 and 1.08, at 20°C and recovering the centrifugation pellet comprising the said PrPres; and, if necessary,

(iii) purification of the PrPres by suspending the centrifugation pellet obtained in (ii) in a Laemmli buffer comprising 1-5% SDS, incubating in this buffer at 100°C for 2-10 minutes and centrifuging at 12,000-15,000 g for 10-15 minutes at 16-22°C.

8. Method of isolating PrPres, from an organ or a tissue, in particular the spleen or the brain, which is capable of being used in a method according to any one of Claims 1 to 6, characterized in that it comprises essentially the following steps:

(i) homogenization of organ or tissue, collected after sacrificing the animal, by mechanical grinding in a homogenization buffer, followed by the addition, to the homogenate obtained, of a salt having a high ionic strength and capable of promoting the aggregation of the PrPres in a 1:1 (v/v) ratio, followed by calibration of the homogenate, for the production of a homogenate comprising, in weight/volume, from 5 to 50% of the said organ or tissue;

(ii) specific extraction of PrPres by treating the homogenate obtained in step (i) by incubating the suspension obtained with solution comprising a protease

09341530-101399

and an anionic detergent capable of promoting the aggregation of the PrPres, and a single separation of the PrPres, by centrifugation at 25,000-60,000 g.h, for example at 25,000-30,000 g for 1 to 2 h, preferably at 5 16-22°C, of the suspension obtained, deposited on a buffer cushion having a density of between 1.02 and 1.08, at 20°C, and recovering the centrifugation pellet comprising the said PrPres; and, if necessary,

(iii) purification of the PrPres by suspending 10 the centrifugation pellet obtained in (ii) in a Laemmli buffer comprising 1-5% SDS, incubating in this buffer at 100°C for 2-10 minutes and centrifuging at 12,000-15,000 g for 10-15 minutes at 16-22°C.

9. Method according to Claim 7 or 8, characterized 15 in that the homogenization buffer in step (i) is in particular a neutral buffer such as water or an isotonic buffer such as 5% glucose.

10. Method according to Claim 7 or Claim 8, characterized in that in step (ii), prior to the 20 centrifugation, at least one protease inhibitor is added.

11. Method according to Claim 7 or Claim 8, characterized in that in step (ii) the centrifugation is preferably carried out after depositing the 25 suspension containing the PrPres on a 6-20% sucrose cushion.

12. Method according to Claim 8, characterized in that during the extraction step (ii) the solution used for the extraction comprises an anionic detergent 30 capable of promoting the aggregation of the PrPres and a zwitterionic detergent, such as a sulphobetaine, preferably the sulphobetaine SB 3-14 at 1-2%, in a 1:1 (v/v) ratio.

13. Method according to Claim 8, characterized in 35 that in the extraction step (ii) the centrifugation is preferably carried out after depositing the suspension containing the PrPres on a cushion comprising, in a mixture, 6-20% sucrose and a sulphobetaine.

09344539-101299

14. Application of a method according to any one of Claims 7 to 13 to the detection of PrPres in an organ or a tissue.

00341539-101299

1/6




FIGURE 1





FIGURE 2

09341539-101299

2/6

FIGURE 3





FIGURE 4

FIGURE 5

5/6






FIGURE 6

**FIGURE 8**

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

ATTORNEY DOCKET NO.:

045636-5027

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR SCREENING SUBSTANCES WITH THERAPEUTIC ACTION IN THE TREATMENT OF TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES

is attached hereto; or

Attorney docket 045636-5027
was filed as United States application Serial No. ~~XXX~~ on July 13, 1999 and was amended on _____ (if applicable); or
PCT/FR98/00063
was filed as PCT international application Number _____ on January 14, 1998 and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119:

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §119
FRANCE	97 00278	14 January 1997	<input checked="" type="checkbox"/> Yes [] No
			[] Yes [] No
			[] Yes [] No
			[] Yes [] No

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.:

045636-5027

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §120:

U.S. APPLICATIONS

STATUS (Check One)

U.S. APPLICATION NO.	U.S. FILING DATE	PATENTED	PENDING	ABANDONED

PCT APPLICATIONS DESIGNATING THE U.S.

STATUS (Check One)

PCT APPLN. NO.	PCT FILING DATE	U.S. SERIAL NO.	PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: as a named inventor, I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Morgan, Lewis & Bockius LLP

Robert J. Gaybrick, Reg. No. 27,890; Richard S. Meyer, Reg. No. 32,541; C. Scott Talbot, Reg. No. 34,262; Reid G. Adler, Reg. No. 30,988; J. Michael Thesz, Reg. No. 40,354; John G. Smith, Reg. No. 33,818; Song K. Jung, Reg. No. 35,210; Matthew T. Bailey, Reg. No. 33,829; Jeffrey A. Lindeman, Reg. No. 34,658; John D. Zele, Reg. No. 39,887; Mary Jane Boswell, Reg. No. 33,652; Michele V. Frank, Reg. No. 37,028; Michael P. Tierney, Reg. No. 35,388; Erin Harriman, Reg. No. 40,410.

Send Correspondence To:

Morgan, Lewis & Bockius LLP
1800 M Street, N.W.
Washington, D.C. 20036-5869

Direct Telephone Calls To:
(name and telephone number)




Reid G. Adler
(202) 467-7756

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

045636-5027

ATTORNEY DOCKET NO.:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	DESLYS Jean-Philippe	
RESIDENCE & CITIZENSHIP	15 allée des Pelouses, 78170 LA CELLE SAINT CLOUD (FRANCE) PRX	COUNTRY OF CITIZENSHIP FRANCE
POST OFFICE ADDRESS	15 allée des Pelouses, 78170 LA CELLE SAINT CLOUD (FRANCE)	
FIRST OR SOLE INVENTOR'S SIGNATURE		DATE Sept. 8, 1999
FULL NAME OF SECOND INVENTOR	BERINGUE Vincent 200	
RESIDENCE & CITIZENSHIP	INA PG Rose des Vents 22, 78850 THIVERVAL GRIGNON (FRANCE) PRX	COUNTRY OF CITIZENSHIP FRANCE
POST OFFICE ADDRESS	INA PG Rose des Vents 22, 78850 THIVERVAL GRIGNON (FRANCE)	
SECOND INVENTOR'S SIGNATURE		DATE Sept. 8, 1999
FULL NAME OF THIRD INVENTOR	LASMEZAS Corinne	
RESIDENCE & CITIZENSHIP	97 rue de Crimée, 75019 PARIS (FRANCE) PRX	COUNTRY OF CITIZENSHIP FRANCE
POST OFFICE ADDRESS	97 rue de Crimée, 75019 PARIS (FRANCE)	
THIRD INVENTOR'S SIGNATURE		DATE Sept. 8, 1999

Listing of Inventors Continued on attached page(s) [] Yes [x] No